<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856619</url>
  </required_header>
  <id_info>
    <org_study_id>TERIFL08918</org_study_id>
    <secondary_id>U1111-1205-3009</secondary_id>
    <nct_id>NCT03856619</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis</brief_title>
  <acronym>SAFE</acronym>
  <official_title>A Single Arm Phase IV Clinical Trial to Describe the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To describe the safety of teriflunomide in patients with relapsing forms of multiple
      sclerosis.

      Secondary Objective:

      To describe the efficacy of teriflunomide in patients with relapsing forms of multiple
      sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration is one year; post treatment safety follow up visit will be conducted 4
      weeks after the patient takes the last dose of teriflunomide
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized relapse rate</measure>
    <time_frame>1 year</time_frame>
    <description>Number of relapses per patient-year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First relapse</measure>
    <time_frame>1 year</time_frame>
    <description>Time to first relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of patients who are relapse free</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological impairment/disability</measure>
    <time_frame>Baseline to 3 months, 6 months, 9 months and 1 year</time_frame>
    <description>Expanded Disability Status Scale (EDSS) will be used to compare disability from baseline. The EDSS ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability progression</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of patients free of disability progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug compliance</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients who are treatment compliant assessed using patient diary</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">193</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Aubagio®/Teriflunomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Aubagio® to be taken orally, once daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TERIFLUNOMIDE HMR1726</intervention_name>
    <description>Pharmaceutical form: Tablet
Route of administration: Oral</description>
    <arm_group_label>Aubagio®/Teriflunomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age of patients ≥ 18 years

          -  Patients with relapsing form of multiple sclerosis at time of screening visit.

          -  Signed written informed consent.

        Exclusion criteria:

          -  Patients with hypersensitivity to teriflunomide, leflunomide, or to any excipients in
             the tablets.

          -  Liver function impairment or persisting elevations of serum glutamic pyruvic
             transaminase (SGPT/ALT), serum glutamic oxaloacetic transaminase (SGOT/AST), greater
             than two times the upper limit of normal (ULN) during screening visit.

          -  Known history of pre-existing acute or chronic liver disease.

          -  Patients with significantly (as per Investigator's discretion) impaired bone marrow
             function or significant anemia, leukopenia, or thrombocytopenia.

          -  Known history of severe immunodeficiency, acute or severe active infections.

          -  Female patients with a positive pregnancy test at screening or women of child-bearing
             potential who do not agree to use effective methods of contraception throughout the
             course of the study.

          -  Male patients unwilling to use reliable contraception during the course of the study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>1 then #</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 024</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 017</name>
      <address>
        <city>Bengaluru</city>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 001</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 023</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 007</name>
      <address>
        <city>Gurgaon</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 026</name>
      <address>
        <city>Gurgaon</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 005</name>
      <address>
        <city>Kochi</city>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 006</name>
      <address>
        <city>Kolkata</city>
        <zip>700068</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 011</name>
      <address>
        <city>Lucknow</city>
        <zip>226001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 020</name>
      <address>
        <city>Ludhiana</city>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 018</name>
      <address>
        <city>Nashik</city>
        <zip>422001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 003</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 025</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 014</name>
      <address>
        <city>Pune</city>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 022</name>
      <address>
        <city>Thiruvananthapuram</city>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

